Collaborative study of children treated for phenylketonuria: study design

Pediatrics
|December 1, 1977
PubMed

Insights

This study addresses challenges in phenylketonuria (PKU) treatment research by using a large, multi-center approach. It establishes a robust design for future collaborative investigations into PKU interventions.

Area of Science:

  • Biomedical Research
  • Metabolic Disorders
  • Pediatric Medicine

Background:

  • Phenylketonuria (PKU) research is often limited by small patient cohorts and confounding variables.
  • Previous treatment effectiveness studies faced challenges due to the rarity of PKU and methodological limitations.
  • A need exists for well-controlled, large-scale studies to accurately assess PKU interventions.

Purpose of the Study:

  • To design and implement a large-scale, multi-center study to overcome limitations in PKU treatment research.
  • To establish controlled conditions for treating a significant number of children with PKU from infancy.
  • To lay the groundwork for future collaborative investigations in rare metabolic disorders.

Main Methods:

  • A collaborative study involving 19 medical centers across 13 states.
  • Treatment of a large cohort of children diagnosed with phenylketonuria (PKU) from near birth.
  • Implementation of controlled conditions and rigorous sampling procedures for data integrity.

Main Results:

  • The study successfully established a large, multi-center collaborative framework for PKU research.
  • Detailed study design and sampling procedures were finalized for ongoing data collection.
  • The methodology is poised to yield significant results in subsequent reports.

Conclusions:

  • The developed study design effectively addresses the limitations of previous PKU treatment research.
  • This collaborative model serves as a benchmark for future large-scale investigations into rare diseases.
  • The study provides a robust foundation for answering critical questions regarding PKU management.

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
165
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
932
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
1.1K